Tenderwize
Retour à la recherche

Open house drug discount agreements Nintedanib

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Mar 03, 2028 · 552 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Nintedanib, ATC L01EX09

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

No estimated contract value or maximum framework value is provided. This makes it impossible to assess the financial op...

Paper submissions require two signed originals sent by mail, and electronic submissions require a qualified electronic...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Non-exclusive discount agreements for Nintedanib (ATC L01EX09) with pharmaceutical companies in Bavaria.
  • Open-house model: any eligible pharmaceutical company can join without selection.
Afficher le résumé complet

Open-house model for non-exclusive drug discount agreements for Nintedanib (ATC L01EX09) by AOK Bayern. Not subject to procurement law. Contracts are offered to all interested pharmaceutical companies that meet eligibility criteria. No selection or award criteria. Contracts run from May 2026 to April 2028, with possible early termination. No estimated value provided.

Risques

No estimated contract value or maximum framework value is provided. This makes it impossible to assess the financial op...

Paper submissions require two signed originals sent by mail, and electronic submissions require a qualified electronic...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Eligibility: only pharmaceutical companies; submit signed self-declaration of reliability.

Administrative

  • Submission: either signed paper copy (two originals) or electronically with qualified electronic signature via DTVP portal.
  • Documents: completed and signed contract, annex listing medicines, and self-declaration of reliability.

Les exigences peuvent être incomplètes.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house drug discount agreements Nintedanib

Non-exclusive discount agreements for the active substance Nintedanib (ATC L01EX09) under §130a(8) SGB V. All eligible pharmaceutical companies can join. Identical, non-negotiable terms. Contracts run from 01.05.2026 to 30.04.2028. Early termination possible with one month notice. Automatic suspension if a competitive discount contract is concluded.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Apr 2026 - Apr 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Mar 03, 2028

Détails de la procédure

Date de publication
15 Mar 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
181186-2026

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30